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Abstract
The association between H. pylori infection and pancreatic cancer risk remains controversial. We 
conducted a nested case-control study with 448 pancreatic cancer cases and their individually 
matched control subjects, based on the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort, to determine whether there was an altered pancreatic cancer risk 
associated with H. pylori infection and chronic corpus atrophic gastritis. Conditional logistic 
regression models were applied to calculate odds ratios (ORs) and corresponding 95% confidence 
intervals (CIs), adjusted for matching factors and other potential confounders. Our results showed 
that pancreatic cancer risk was neither associated with H. pylori seropositivity (OR=0.96; 95% CI: 
0.70, 1.31) nor CagA seropositivity (OR=1.07; 95% CI: 0.77, 1.48). We also did not find any 
excess risk among individuals seropositive for H. pylori but seronegative for CagA, compared with 
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the group seronegative for both antibodies (OR=0.94; 95% CI: 0.63, 1.38). However, we found 
that chronic corpus atrophic gastritis was non-significantly associated with an increased pancreatic 
cancer risk (OR=1.35; 95% CI: 0.77, 2.37), and although based on small numbers, the excess risk 
was particularly marked among individuals seronegative for both H. pylori and CagA (OR=5.66; 
95% CI: 1.59, 20.19, p value for interaction < 0.01). Our findings provided evidence supporting 
the null association between H. pylori infection and pancreatic cancer risk in western European 
populations. However, the suggested association between chronic corpus atrophic gastritis and 
pancreatic cancer risk warrants independent verification in future studies, and, if confirmed, 
further studies on the underlying mechanisms.
Keywords
H. pylori infection; chronic corpus atrophic gastritis; pancreatic cancer risk; nested case-control 
study; EPIC cohort
Introduction
Pancreatic cancer is one of the most devastating malignancies and has the lowest five-year 
survival proportion1–4. It ranks the fourth or fifth leading cause of cancer-related death for 
men and women in developed countries2, and it is estimated to become the second leading 
cause of cancer-related death in the U.S. by 20205. Established risk factors include old age, 
male sex, tobacco smoking, chronic pancreatitis, type 2 diabetes mellitus, obesity and a 
family history of pancreatic cancer6. Besides, ABO blood type has recently also been 
proposed as a risk factor for pancreatic cancer7, although the first study to explore this 
association was conducted half a century ago in the context of examination between ABO 
blood types and multiple malignant diseases8. Yet, the etiology of pancreatic cancer is not 
fully understood as the identified risk factors explain only around 40% of all pancreatic 
cancer cases in the UK9. Further search for its etiological factors and understanding of the 
related mechanisms are urgently needed.
Helicobacter pylori (H. pylori), a group I carcinogen defined by IARC10, has been 
established and widely accepted to play an important role in the development of noncardia 
gastric cancer10, 11. One type of H. pylori strains contains a gene associated with cytotoxin 
expression, namely CagA positive H. pylori. The CagA gene was found to lead to enhanced 
inflammatory responses and an increased risk for gastric cancer12, 13. However, results from 
previous epidemiologic studies on its association with pancreatic cancer are inconsistent. 
One meta-analysis containing four European studies showed a pooled 56% excess pancreatic 
cancer risk among H. pylori infected individuals14, but another meta-analysis with seven 
studies from Western countries did not confirm this association15. However, a recent meta-
analysis study suggested that an increased risk of pancreatic cancer among individuals of 
CagA-negative H. pylori seropositivity16. Nevertheless, the prevalence of H. pylori infection 
and distribution of strains (CagA+ or CagA-) vary greatly throughout the world, with a 
higher prevalence of overall infection and CagA+ strains predominantly in Asia compared 
with the U.S. and Europe.
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Chronic corpus atrophic gastritis is a precursor lesion of gastric cancer and is characterized 
by long-term chronic gastric inflammation. Autoimmune pernicious anemia, chronic H. 
pylori infection and long period proton pump inhibitor therapy are identified as risk factors 
of chronic corpus atrophic gastritis17–19. We hypothesized that chronic corpus atrophic 
gastritis may be associated with an increased pancreatic cancer risk, through a stomach low-
acid-production mechanism that may subsequently entail bacterial overgrowth and enhance 
accumulation of N-nitrosamines.
To further examine the associations between H. pylori infection, chronic corpus atrophic 
gastritis and pancreatic cancer risk, we conducted a case-control study nested within the 
large European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
Methods
Study population
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a large cohort 
study that enrolled 520,000 apparently healthy volunteers, age 25 to 70, from 23 centers in 
10 European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, 
Norway, Sweden, and the United Kingdom) from 1992 to 2000. Details in study design, 
population and baseline data collection have been described previously20. The study was 
approved by Institutional Ethics Review Board of each participating center, and each 
participant provided informed consent. This specific project was further approved by the 
Regional Ethics Review Board in Stockholm, Sweden.
Ascertainment of cases and control selection
Follow-up of subject to detect cancer incidence was based on population cancer registers in 
Denmark, Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom. In the 
other three countries (France, Germany and Greece), a combined approach was employed 
including linkage to health insurance records, cancer and pathology registers, and active 
follow-up of study participants and their next-of-kin. All the mortality data was provided by 
regional or national registers. All the participants were followed from their recruitment to a 
cancer diagnosis, death, emigration, or the end of follow-up (Dec, 2006), whichever 
occurred first.
Until the end of 2006, a total of 578 first incident pancreatic cancer cases were identified 
according to International Classification of Diseases, 10th Revision (ICD-10, C25.0–25.3, 
25.7–25.9). Due to the different etiology, endocrine pancreatic tumor (ICD -O-3 C25.4, 
histologic type and morphology codes 8150, 8151, 8153, 8155, 8240 and 8246) were not 
included in this study. We further excluded individuals without blood samples, leaving a 
total of 448 cases in the final analysis. By using an incidence density sampling procedure, 
each identified case was individually matched with one control that was alive and free of 
cancer at the time when the index case was diagnosed. The matching factors included study 
center, sex, age (±3 years), date (±3 months), time (±2 h), and fasting status (<3h, 3–6h or 
>6 after the last meal) at blood collection.
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Biomarkers and exposure assessment
Determination of H. pylori serostatus—Seroprevalence of anti-H. pylori antibodies 
was determined by enzyme-linked immunosorbent assay (ELISA) using the commercial H. 
pylori IgG kit from Biohit (Helsinki, Finland). The enzyme immunounits (EIU) were 
calculated as following: sample EIU= [mean optical density (OD) value of sample-mean OD 
value of blank]/[mean OD value of calibrator-mean OD value of blank]*100; A value of 30 
EIU or more was considered as positive.
Determination of CagA serostatus—Seroprevalence of anti-CagA antibodies was 
determined by ELISA using the commercial H. pylori p120 (CagA) IgG kit from Ravo 
Diagnostika GmbH (Freiburg, Germany). The EIU were calculated as following: sample 
EIU= [mean OD value of sample-mean OD value of blank]/[mean OD value of calibrator-
mean OD value of blank]*unit value of calibrator; A value of 7.5 EIU or more was 
considered as positive.
Determination of pepsinogen I and pepsinogen II levels—Serum levels of 
pepsinogen I and II were determined by pepsinogen I and pepsinogen II ELISA kits from 
Biohit (Helsinki, Finland). A calibration curve was generated to calculate the pepsinogen I 
or II concentration. A pepsinogen I level < 25 µg/l or pepsinogen I/II <3 was considered as 
presence of chronic corpus atrophic gastritis21.
For quality control, the laboratory staff was blinded to the case/control status and in each 
plate duplicate internal control serum samples were added. All the tested samples, including 
positive control, calibration samples and internal control samples, yielded titer values well 
within their appropriate ranges; coefficients of variation calculated from values of the 
internal controls, were 9.7% for H. pylori, 10.3% for CagA, 5.0% for pepsinogen I and 7.9% 
for pepsinogen II assay, respectively.
Determination of ABO blood group—The common ABO blood type was determined 
by genotyping 2 known SNPs, rs505922 and rs8176746, which are correlated with the O and 
B alleles, respectively7.
Statistical analysis
Differences of baseline characteristics between cases and control subjects were tested by 
paired t-test for continuous variables, and by McNemar’s test or generalized McNemar’s test 
for categorical variables. We used a conditional logistic regression model with stratified 
case-control risk sets to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for 
the associations between H. pylori infection, Cag A seropositivity, chronic corpus atrophic 
gastritis and pancreatic cancer risk. The crude conditional logistic regression models were 
inherently adjusted for the matching factors (mentioned above). We further considered 
smoking status (never, former or current), diabetes mellitus status (no or yes), height, and 
waist-to-hip ratio, a proxy of central obesity, as potential confounders and adjusted them in 
the models.
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To estimate blood group stratum-specific effects, a 4-category new variable was generated 
by combining two dichotomous variables, i.e. H. pylori/CagA seropositivity (H. pylori– and 
CagA– vs H. pylori + or CagA+) and blood group (O vs non-O); dummy variables were then 
created and entered into regression models. The effect of H. pylori/CagA seropositivity on 
pancreatic cancer risk in O or non-O blood group strata was estimated by using different 
reference groups. To examine whether the association between H. pylori and/or CagA 
serostatus and pancreatic cancer was significantly modified by ABO blood group (O vs non-
O blood type), a multiplicative interaction term was introduced into the regression model 
and p value for the interaction term was derived from a Wald test. Similarly the stratum-
specific effects of chronic corpus atrophic gastritis by H. pylori/CagA serostatus were 
estimated, and the interaction between these two variables was examined. Again, in order to 
explore the modification effect of smoking (never vs ever) for the association between H. 
pylori /CagA serostatus and pancreatic cancer risk, the interaction term between these two 
variables was introduced into the regression model and p value was derived.
Socioeconomic status (SES) might also be a potential confounder that is both related to H. 
pylori infection and pancreatic cancer risk. We further performed a sensitivity analysis by 
adjusting SES in the models. The highest achieved educational level, which was classified 
into four categories (primary education or less, vocational secondary education, other 
secondary education, college or university), was used as the proxy for SES.
To check the influence of reverse causation bias, a sensitivity analysis was further performed 
by excluding cases (and their matched controls) who were diagnosed within the first two 
years of follow-up. In order to minimize the influence of non-fasting status of blood 
samples, we conducted another sensitivity analysis by only including case patients and their 
matched controls with the fasting status of more than six hours since the last meal to blood 
collection.
All statistical analyses were conducted using the Statistical Analysis System (SAS) software 
package, version 9.3 (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-
sided and statistical significance level was set at the 5% level.
Results
The mean age at recruitment was 57.8 years for both cases and control subjects. Cases did 
not significantly differ from control subjects for height and waist-to-hip ratio. In contrast, 
compared to control subjects, cases were more likely to be current smokers and tended to 
have a history of diabetes at baseline of recruitment. Female pancreatic cancer cases had a 
significantly higher weight compared to their corresponding controls. Overall, the 
prevalence of H. pylori seropositivity, CagA seropositivity and serologically defined chronic 
corpus atrophic gastritis did not differ significantly between cases and control subjects 
(Table 1).
Based on the crude models, our results showed that pancreatic cancer risk was neither 
associated with H. pylori seropositivity (OR=0.91; 95% CI: 0.68, 1.21) nor CagA 
seropositivity (OR=1.02; 95% CI: 0.76, 1.38). Further adjustment for potential confounding 
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factors including height, waist-to-hip ratio, smoking status (never, former or current) and 
diabetes mellitus status (no or yes) had a negligible effect on the associations (Table 2). We 
did not find any association between pancreatic cancer risk and H. pylori/CagA 
seropositivity, in either never smokers or ever smokers (p value for interaction = 0.11, fully-
adjusted model) (data not shown).
In the combined analysis of H. pylori and CagA serostatus, compared with those 
seronegative for both H. pylori and CagA, the OR was close to unity for those seropositive 
for either H. pylori or CagA (OR=0.99; 95%CI: 0.73, 1.35, fully-adjusted model). The null 
associations were consistent across subgroups with different combinations of H. pylori and 
CagA serostatus (Table 2). In the sub-analysis among those with complete ABO blood type 
information (278 cases and their matched controls), we further performed a combined 
analysis of H. pylori/CagA serostatus and ABO blood type. We did not observe any excess 
risk of pancreatic cancer related to H. pylori/CagA seropositivity, in either O or non-O blood 
group (p value for interaction = 0.46, fully-adjusted model) (Table 2).
On the contrary, our results indicated that chronic corpus atrophic gastritis was positively, 
although not statistically significantly, associated with pancreatic cancer risk (OR=1.35; 
95% CI: 0.77, 2.37, fully-adjusted model). To examine the modification effect of H. pylori 
infection on the association between chronic corpus atrophic gastritis and pancreatic cancer 
risk, we further performed stratified analyses and found that the positive association was 
confined to the stratum seronegative for both H. pylori and CagA (OR=5.66, 95% CI: 1.59, 
20.19, p value for interaction < 0.01, fully-adjusted model) (Table 3).
In the sensitivity analysis by further adjusting for SES in the models, the results did not 
change notably (data not shown). In another sensitivity analysis to examine the influence of 
reverse causation bias, we excluded pancreatic cancer cases identified within two years of 
follow-up and their matched controls (N=83 case-control pairs), the results did not alter 
appreciably (data not shown). Similarly, including only the case-control sets with fasting 
status of more than six hours since the last meal in the analysis, the results did not change 
remarkably (data not shown).
Discussion
This case-control study nested within a large European prospective cohort study showed no 
evidence supporting the association between H. pylori infection (indicated by either H. 
pylori seropositivity or CagA seropositivity, or a combination of both) and pancreatic cancer 
risk. The lack of association was still evident in stratified analysis by ABO blood type. 
Although based on small numbers, our results provided some support that severe chronic 
corpus atrophic gastritis, defined by serological pepsinogen levels, might be associated with 
an increased pancreatic cancer risk.
A number of previous studies have addressed the potential association between H. pylori 
infection and pancreatic cancer risk. The first study was a hospital-based case-control study 
reported in 199822, including 92 pancreatic cancer cases and 62 controls (35 colorectal 
cancer patients and 27 healthy volunteers), in which a 2-fold excess risk of pancreatic cancer 
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was associated with H. pylori seropositivity. This positive association was later confirmed by 
a case-control study nested within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
cohort and the association seemed to be stronger for CagA seropositivity23. However, in two 
later population-based case-control studies conducted in the U.S. and China24, 25, excess risk 
of pancreatic cancer was found to be associated with CagA-negative H. pylori infection only, 
in particular among those with non-O blood type24. In a Swedish case-control study nested 
within a prospective cohort, although overall H. pylori seropositivity was not associated with 
pancreatic cancer risk, positive associations were observed among never-smokers or low 
alcohol consumers26. The small numbers of cases in stratified analyses, however, cautioned 
interpretation of the findings. In contrast to the above-mentioned positive associations, three 
studies reported null associations between H. pylori seropositivity and pancreatic 
cancer27–29. In the two case-control studies nested within prospective cohort studies in the 
U.S. and Finland, neither H. pylori nor CagA was associated with pancreatic cancer 
development27, 28. Of note, the study in Finland28 was an updated report based on extended 
follow-up of the same study cohort, from which a significant positive association was 
reported in 200123. In a small clinical study conducted in Japan, the authors found that H. 
pylori seroprevalence was similar between pancreatic cancer cases and controls29. 
Discrepancies of results reported in previous studies may be explained by small sample size, 
various study designs and study populations, different methods of assessment of H. pylori 
infection, unmeasured confounders, and differential joint effects of environmental and/or 
genetic factors.
Various underlying mechanisms have been proposed to explain the potential association 
between H. pylori infection and pancreatic cancer risk. One plausible mechanism involves 
antral colonization of H. pylori which may lead to an excess of gastric acidity, that can 
stimulate uninhibited secretin release from the duodenum and induce basal pancreatic ductal 
bicarbonate output. This will in turn result in pancreatic ductular hyperplasia through 
increased DNA synthesis30. Another potential mechanism, in contrast to an excess of gastric 
acidity, is related to the sequential pathologic alterations during the gastric cancer 
carcinogenesis. It has been proposed that the long-term pathogenesis process after gastric 
colonization of H. pylori usually goes via chronic superficial gastritis, chronic atrophic 
gastritis, metaplasia and dysplasia31. The development of multifocal atrophic gastritis may 
cause a loss of parietal cells, leading to a hypo- or achlorhydria and basal hypergastrinemia, 
which subsequently entails the bacterial overgrowth and enhances N-nitrosation 
catalyzation32; through the blood stream circulation, the N-nitrosamines may transport to the 
pancreas, and the carcinogens may be activated on the ductal epithelium33. The latter 
hypoacidity mechanism is supported by a register-based Swedish study34, in which an 
elevated pancreatic cancer risk was observed among patients with gastric ulcer, but not 
among those with duodenal ulcer. Duodenal ulcer is related to antral colonization of H. 
pylori and hyperchlorhydria, whereas gastric ulcer is linked to infection on the gastric corpus 
with normo- or hypochlorhydria. Another supportive evidence for the hypoacidity 
mechanism comes from the observed excess risk of pancreatic cancer among patients with 
pernicious anemia which is characterized by long-term hypo- or achlorhydria35, 36. Although 
not conclusive, our results tended to support the above-mentioned hypoacidity mechanism.
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Few studies have directly examined the association between chronic corpus atrophic gastritis 
and pancreatic cancer risk. In a Finnish study on male smokers, the authors found that 
neither low pepsinogen level nor histologically confirmed atrophic gastritis was associated 
with subsequent pancreatic cancer risk37. However, in our study, we found a significant 
positive association between chronic corpus atrophic gastritis and pancreatic cancer in the 
stratum seronegative for both H. pylori and CagA, but not in the stratum seropositive for H. 
pylori or CagA. Given the very small number of study subjects in the seronegative stratum 
(only three controls with chronic corpus atrophic gastritis), caution is needed in interpreting 
this finding. One possible explanation may be due to that in the seronegative stratum, 
chronic corpus atrophic gastritis might be more severe. In addition, previous studies have 
found that long-term advanced chronic corpus atrophic gastritis might result in clearance of 
H. pylori colonization of the stomach mucosa, and in turn result in lower antibodies against 
the bacterium38, 39. However, we still cannot rule out the possibility that the observed 
positive association was explained by chance, given the relatively small sample size in this 
subgroup. Confirmatory studies are warranted to reexamine this association.
The strengths of this study include a prospective study design with prediagnostic blood 
samples collected, highly complete follow-up and availability of detailed information of 
potential confounding factors. However, our findings should be interpreted carefully due to 
several limitations. Misclassification of exposures of interest, such as H. pylori infection and 
presence of chronic corpus atrophic gastritis, might exist, although it is most likely to be 
non-differential, as we had to rely on measuring serum antibodies against H. pylori/CagA 
and pepsinogen I/II levels. For chronic corpus atrophic gastritis, the ‘gold standard’ of 
diagnosis is based on histopathological examination which requires biopsies during an upper 
gastrointestinal endoscopy examination, but this is impossible to apply in large-scale 
epidemiological studies. In addition, we used ABO rs505922 to determinate O blood alleles. 
Although it has high linkage disequilibrium with rs8176719, it still cannot be a complete 
replacement for the functional variant of rs817671940. Therefore, the genotyping 
measurement error might exist and result in non-differential misclassification of O and non-
O blood type in the present study.
In conclusion, neither H. pylori seropositivity nor CagA status was directly associated with 
pancreatic cancer risk. The lack of association remained consistent regardless of ABO blood 
type. However, we found some supportive evidence that chronic corpus atrophic gastritis 
might be associated with a higher pancreatic cancer risk, especially among H. pylori 
seronegative group. Future studies are warranted to verify this observation, and if confirmed, 
to further explore the underlying mechanisms.
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The association between H. pylori infection and pancreatic cancer risk remains 
controversial. In this nested case-control study of 448 pancreatic cancer cases and 
individually matched controls, our findings provided evidence supporting the null 
association between H. pylori infection and pancreatic cancer risk in western European 
populations. However, we found some supportive evidence that chronic corpus atrophic 
gastritis might be associated with a higher pancreatic cancer risk, especially among H. 
pylori seronegative group.
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Table 1
Baseline characteristics of cases with pancreatic cancer and control subjects1
Factor Controls (N=448) Cases (N=448) P-value2
Age at recruitment (years, mean ± SD) 57.8 ± 7.8 57.8 ± 7.8 matched
Sex, n (%) matched
Male 213 213
Female 235 235
Age at blood collection (±3 years) 58.0 ± 7.8 58.0 ± 7.8 matched
Fasting status, n (%) matched
Fasting (≥6 h) 104 (23.2) 112 (25.0)
In between (3–6 h) 69 (15.4) 68 (15.2)
Not-fasting (<3 h) 172 (38.4) 172 (38.4)
Unknown 103(23.0) 96 (21.4)
Height (cm, mean ± SD)
Male 175.1 ± 7.6 174.6 ± 7.3 0.68
Female 161.4 ± 7.0 162.2 ± 6.5 0.19
Weight (kg, mean ± SD)
Male 82.1 ± 12.6 81.7 ± 11.7 0.69
Female 65.6 ± 11.0 69.5 ± 13.3 0.0004
Waist to hip ratio (mean ± SD)
Male 0.95 ± 0.06 0.95 ± 0.06 0.62
Female 0.81 ± 0.06 0.81 ± 0.07 0.15
Smoking status (%)
Never 194 (43.3) 165 (36.8)
Former 153 (34.2) 140 (31.3)
Current 96 (21.4) 138 (30.8) 0.002
Unknown 5 5
History of diabetes mellitus (%)
No 409 (95.6) 397 (92.8)
Yes 19 (4.4) 31 (7.2) 0.09
Unknown 20 20
Pepsinogen I, n (%)
Low (<25) 14 (3.2) 20 (4.5)
High (≥25) 427 (96.8) 422 (95.5) 0.29
Missing 7 6
Pepsinogen I/II, n (%)
Low (<3) 25 (5.7) 28 (6.3)
High (>3) 416 (94.3) 414 (93.7) 0.66
Missing 7 6
H. pylori, n (%)
HP negative 241 (53.9) 250 (56.1)
HP positive 206 (46.1) 196 (44.0) 0.50
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Factor Controls (N=448) Cases (N=448) P-value2
Missing 1 2
CagA, n (%)
CagA negative 306 (68.9) 302 (68.3)
CagA positive 138 (31.1) 140 (31.7) 0.88
Missing 4 6
1
Cases and control subjects were 1:1 matched on center, sex, age at blood collection (±3 years), date of blood donation (±3 months), time of blood 
donation (±2 h), and fasting status (<3h, 3–6h or >6 after the last meal).
2
P values were derived from paired t test for continuous variable, and from McNemar’s test or generalized McNemar’s test for categorical 
variables.
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